An Efficient Method for the In Vitro Production of Azol(in)e-Based Cyclic Peptides
Heterocycle‐containing cyclic peptides are promising scaffolds for the pharmaceutical industry but their chemical synthesis is very challenging. A new universal method has been devised to prepare these compounds by using a set of engineered marine‐derived enzymes and substrates obtained from a famil...
Saved in:
Published in | Angewandte Chemie International Edition Vol. 53; no. 51; pp. 14171 - 14174 |
---|---|
Main Authors | , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Weinheim
WILEY-VCH Verlag
15.12.2014
WILEY‐VCH Verlag Wiley Wiley Subscription Services, Inc |
Edition | International ed. in English |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Heterocycle‐containing cyclic peptides are promising scaffolds for the pharmaceutical industry but their chemical synthesis is very challenging. A new universal method has been devised to prepare these compounds by using a set of engineered marine‐derived enzymes and substrates obtained from a family of ribosomally produced and post‐translationally modified peptides called the cyanobactins. The substrate precursor peptide is engineered to have a non‐native protease cleavage site that can be rapidly cleaved. The other enzymes used are heterocyclases that convert Cys or Cys/Ser/Thr into their corresponding azolines. A macrocycle is formed using a macrocyclase enzyme, followed by oxidation of the azolines to azoles with a specific oxidase. The work is exemplified by the production of 17 macrocycles containing 6–9 residues representing 11 out of the 20 canonical amino acids.
Heterocycle‐containing cyclic peptides are promising scaffolds for the pharmaceutical industry, but their chemical synthesis is very challenging. A new universal method has been devised to prepare these compounds by using a set of engineered marine‐derived enzymes and substrates. |
---|---|
Bibliography: | BBSRC - No. BB/K015508/1 Funded Access TSB - No. 131181 This work was supported by grants from the Leverhulme Trust RPG-2012-504 (M.J., M.C.M.S., and J.H.N.), TSB 131181 (M.J., J.H.N., and W.E.H.), ERC 339367 (J.H.N. and M.J.) MSD-SULSA (M.J. and A.R.M.), BBSRC BB/K015508/1 (J.H.N. and M.J.). J.T. is funded by EU-FP7 contract Pharmasea 312184. W.E.H is the recipient of the SULSA Leaders award. We thank the BSRC mass spectrometry facility at the University of St Andrews and Aberdeen Proteomics Facility for extensive sample analysis. This research is funded in part by the MSD Scottish Life Sciences fund. As part of an on-going contribution to Scottish life sciences, Merck Sharp & Dohme (MSD) has given substantial monetary funding to the Scottish Funding Council (SFC) for distribution via the Scottish Universities Life Science Alliance (SULSA) The opinions expressed in this research article are those of the authors and do not necessarily represent those of MSD or its affiliates. Leverhulme Trust - No. RPG-2012-504 ark:/67375/WNG-7H60SM6S-W ERC - No. 339367 istex:3A738A10CEE461E10F99684B2D656869E2D68690 ArticleID:ANIE201408082 These authors contributed equally to this work. This work was supported by grants from the Leverhulme Trust RPG‐2012‐504 (M.J., M.C.M.S., and J.H.N.), TSB 131181 (M.J., J.H.N., and W.E.H.), ERC 339367 (J.H.N. and M.J.) MSD‐SULSA (M.J. and A.R.M.), BBSRC BB/K015508/1 (J.H.N. and M.J.). J.T. is funded by EU‐FP7 contract Pharmasea 312184. W.E.H is the recipient of the SULSA Leaders award. We thank the BSRC mass spectrometry facility at the University of St Andrews and Aberdeen Proteomics Facility for extensive sample analysis. This research is funded in part by the MSD Scottish Life Sciences fund. As part of an on‐going contribution to Scottish life sciences, Merck Sharp & Dohme (MSD) has given substantial monetary funding to the Scottish Funding Council (SFC) for distribution via the Scottish Universities Life Science Alliance (SULSA) The opinions expressed in this research article are those of the authors and do not necessarily represent those of MSD or its affiliates. researchfish UKRI ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 1433-7851 1521-3773 |
DOI: | 10.1002/anie.201408082 |